EP3997128A4 - Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern - Google Patents

Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern Download PDF

Info

Publication number
EP3997128A4
EP3997128A4 EP20836912.4A EP20836912A EP3997128A4 EP 3997128 A4 EP3997128 A4 EP 3997128A4 EP 20836912 A EP20836912 A EP 20836912A EP 3997128 A4 EP3997128 A4 EP 3997128A4
Authority
EP
European Patent Office
Prior art keywords
hsc
patient
hematopoietic
stem cells
specific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20836912.4A
Other languages
English (en)
French (fr)
Other versions
EP3997128A1 (de
Inventor
Vladislav Sandler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemogenyx Pharmaceuticals LLC
Original Assignee
Hemogenyx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/506,764 external-priority patent/US11104738B2/en
Application filed by Hemogenyx Pharmaceuticals LLC filed Critical Hemogenyx Pharmaceuticals LLC
Publication of EP3997128A1 publication Critical patent/EP3997128A1/de
Publication of EP3997128A4 publication Critical patent/EP3997128A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EP20836912.4A 2019-07-09 2020-07-08 Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern Withdrawn EP3997128A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,764 US11104738B2 (en) 2016-04-04 2019-07-09 Monoclonal antibodies to human FLT3/FLK2 receptor protein
PCT/US2020/041095 WO2021007266A1 (en) 2019-07-09 2020-07-08 Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies

Publications (2)

Publication Number Publication Date
EP3997128A1 EP3997128A1 (de) 2022-05-18
EP3997128A4 true EP3997128A4 (de) 2023-10-18

Family

ID=74115143

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20836912.4A Withdrawn EP3997128A4 (de) 2019-07-09 2020-07-08 Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern

Country Status (5)

Country Link
EP (1) EP3997128A4 (de)
JP (1) JP2022540602A (de)
CN (1) CN114829399A (de)
CA (1) CA3146912A1 (de)
WO (1) WO2021007266A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017015453A2 (pt) * 2015-01-26 2018-01-23 Cellectis células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides
CN109562164B (zh) * 2016-04-04 2022-10-04 海默珍科医药有限责任公司 使用双特异性抗体消除患者中的造血干细胞/造血祖细胞(hsc/hp)的方法
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180110832A1 (en) * 2015-04-20 2018-04-26 The Board Of Regents Of The University Of Texas Sy Stem Clec11a is a bone growth agent
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells

Also Published As

Publication number Publication date
WO2021007266A1 (en) 2021-01-14
CN114829399A (zh) 2022-07-29
EP3997128A1 (de) 2022-05-18
CA3146912A1 (en) 2021-01-14
JP2022540602A (ja) 2022-09-16

Similar Documents

Publication Publication Date Title
EP3439699A4 (de) Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern
EP3924375A4 (de) Universalspenderstammzellen und zugehörige verfahren
EP3914271A4 (de) Zusammensetzungen und verfahren zur erzeugung von hämatopoetischen stammzellen (hscs)
EP4029947A4 (de) Verfahren zur herstellung von pflanzenproteinkonzentrat
EP3802790A4 (de) Verfahren zur erzeugung von hämatopoetischen stammzellen
EP4024533A4 (de) Sekundärbatterie, gerät mit sekundärbatterie, herstellungsverfahren für sekundärbatterie und klebstoffzusammensetzung
EP3969560A4 (de) Mikrofluidische vorrichtung und verfahren zur verwendung zur zellzüchtung
EP4072570A4 (de) Verfahren zur erzeugung von hämatopoetischen stammzellen
EP3980067A4 (de) Antikörper-interleukin-fusionsprotein und anwendungsverfahren
EP3938400A4 (de) Cd22-antikörper und verfahren zur verwendung davon
EP4028525A4 (de) Kombinierte expression eines chimären cd3 fusionsproteins und eines bispezifischen t-zell-aktivierenden elements auf der basis von anti-cd3
IL294152A (en) A method for culturing hematopoietic stem cells
EP3976066A4 (de) Verfahren zur erzeugung und expansion von hämatopoetischen stammzellen
EP3959996A4 (de) Emulsionszusammensetzung mit saatspeicherprotein und verfahren zu deren herstellung
AU2022241885A1 (en) Methods for obtaining induced pluripotent stem cells
EP3997128A4 (de) Verfahren zur eliminierung von hämatopoetischen stammzellen/hämatopoetischen vorläuferzellen (hsc/hp) in einem patienten mit bi-spezifischen antikörpern
EP3985103A4 (de) Zellen mit fähigkeit zur differenzierung in plazentakonstituierende zellen und verfahren zu ihrer herstellung
EP3933022A4 (de) Verfahren zur herstellung eines kulturgefässes und kulturgefäss
EP4051782A4 (de) Medium und verfahren zur kultivierung von organoiden
EP3947660A4 (de) Enpp1-polypeptide und verfahren zu deren verwendung
EP3979360A4 (de) Feststoffbatterie und verfahren zur herstellung davon
EP3778865A4 (de) Neuartige zelle und verfahren zur herstellung eines proteins von interesse unter verwendung davon
EP4022795A4 (de) Vorrichtungen und verfahren zur sequenziellen empfangskombination
EP3922115A4 (de) Wegwerfbare doppelkanalzigarette und herstellungsverfahren dafür
EP3950932A4 (de) Verfahren zur herstellung pluripotenter stammzellen mit fähigkeit zur differenzierung in spezifische zellen und deren verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230606BHEP

Ipc: A61P 37/06 20060101ALI20230606BHEP

Ipc: A61K 45/06 20060101ALI20230606BHEP

Ipc: A61K 39/395 20060101ALI20230606BHEP

Ipc: C07K 16/28 20060101AFI20230606BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230914

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230908BHEP

Ipc: A61P 37/06 20060101ALI20230908BHEP

Ipc: A61K 45/06 20060101ALI20230908BHEP

Ipc: A61K 39/395 20060101ALI20230908BHEP

Ipc: C07K 16/28 20060101AFI20230908BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240219